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ABSTRACT 
 
c-MET is a receptor tyrosine kinase that, after binding with its ligand, hepatocyte 
growth factor (HGF), activates many signaling pathways, driving proliferation, 
motility, migration and invasion. Although c-MET is important in the control of tissue 
homeostasis under normal physiological conditions, it has also been found to be 
aberrantly activated in human cancers via mutation, amplification or protein 
overexpression. Activating point mutations were identified in the kinase domain of 
MET, either in the germline of patients affected by hereditary papillary renal 
carcinoma (HPRC) or in spontaneously occurring tumors; in particular, nine missense 
mutations (defined METPRC mutations), leading to constitutive activation of MET 
protein, have been identified in HPRC families. Given the importance of MET as a 
target for cancer therapies, clinical trials aimed at inhibiting it through the use of 
tyrosine kinase inhibitors (TKIs) have recently been started.  
The aim of project was: (i) to evaluate if METPRC mutants are sensitive to PHA-
665752 (a small kinase inhibitor of MET), (ii) if some mutants are insensitive to the 
inhibitor, to investigate the mechanisms responsible for resistance, (iii) to check if the 
resistant mutants are still sensitive to other chemicals inhibitors or monoclonal 
antibodies against MET, (iv) to identify activating point mutations in human 
surgically resected lung cancers.  
We have found that some METPRC mutants cannot be inhibited by PHA-665752. 
Treatment with this TKI does not alter either receptor phosphorylation or MET 
mutants-induced biological activities (migration, invasion, anchorage-independent 
growth). We showed that these mutants are insensitive also to JNJ-38877605, a 
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multitargeted tyrosine kinase inhibitor.. When we performed the mutational analysis 
on lung cancer samples, in one tumor we found the presence of one of the 
identified“resistant” mutations.  
To determine whether the mutants resistant to PHA-665752 could be inhibited with 
other strategies, we treated the mutant-expressing cells with the monoclonal antibody 
DN30, directed against the extracellular portion of the receptor. Our results showed 
that DN30 was indeed able to inhibit all the METPRC mutants.  
In conclusion, we have identified some METPRC  mutants which do not respond to the 
ATP competitive kinase inhibitors. Since the identified METPRC mutations are located 
in the kinase domain and alter its conformation; it is likely that the competitive 
inhibitors are unable to interact with the ATP binding site in the context of the 
mutated receptors; this would render these mutants "resistant" to the action of tyrosine 
kinase inhibitors. However, these mutated forms still remain responsive to treatment 
antibodies directed against the MET extracellular portion: This observation is 
important since the use of monoclonal antibodies represent a therapeutic alternative 
for patients with tumors carrying MET mutants resistant to TKIs. 
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The MET (HGF receptor) tyrosine kinase. 
The MET gene, discovered as an oncogene more than two decades ago (Trusolino,L. 
and Comoglio,P.M., 2002; Cooper,C.S. et al. 1984), encodes for a tyrosine kinase 
receptor that binds to, and is activated by, the growth and motility factor HGF (also 
called Scatter Factor 1). The MET receptor is a disulphide-linked heterodimer  
composed of an extracellular 50-kDa  chain and transmembrane 145-kDa  chain. 
The extracellular moiety contains a conserved “Sema” domain of 500 amino acids, 
known to be a protein-protein interaction domain, and a cystein-rich motif of 80 
amino acids, called MET related sequence (MRS). The intracellular portion of the 
receptor can be divided into three functional domains: i) a juxtamembrane domain, 
playing an inhibitory function through a serine residue (S985) phosphorylated by 
protein kinase C or Ca2+/calmodulin-dependent kinases (Gandino,L. et al. 1994) and 
a tyrosine residue (Y1003) that, upon phosphorylation, binds to the E3 ubiquitin 
ligase Cbl which promotes receptor ubiquitinylation, endocytosis and degradation; ii) 
the tyrosine kinase catalytic domain, that contains the major phosphorylation site 
represented by the tyrosine residues 1234 and 1235, whose activity is induced in an 
autocatalytic fashion by receptor trans-phosphorylation (Naldini,L. et al. 1991); and 
iii) a carboxi-terminal tail with a unique docking site responsible for the recruitment 
of a wide spectrum of downstream signaling molecules; among them are the 
phosphatidylinositol 3-kinase (PI3K), the GRB2/SOS complex, the non-receptor 
tyrosine kinase Src, the transcription factor STAT3  and the adaptors Shc and Gab-1, 
that provide additional docking sites for many signaling molecules.  
All the structural features described so far define a receptor family (the “Scatter 
Factor Receptor Family”) comprising, besides MET, also Ron (Macrophage 
Stimulating Protein Receptor) and its chicken orthologue Sea.  
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Fig 1.1 
 MET is a single-pass, disulphide-linked /  heterodimer that is formed by proteolytic processing of a 
common precursor in the post-Golgi compartment. The extracellular portion of MET is composed of 
three domain types. The N-terminal 500 residues fold into a large Sema domain, which encompasses 
the whole -subunit and part of the -subunit, and shares sequence homology with domains found in 
the semaphorin and plexin families. The Sema domain is followed by a PSI domain – also found in  
plexins, semaphorins and integrins,– that spans about 50 residues and contains four disulphide bonds. 
The PSI domain is connected to the transmembrane helix via four IPT domains, which are related to 
immunoglobulin-like domains and are named after their presence in plexins and transcription factors. 
The intracellular portion includes the tyrosine kinase catalytic site flanked by distinctive 
juxtamembrane and carboxy-terminal sequences. Phosphorylation of Tyr1234 and Tyr1235 within the 
catalytic site positively modulates the enzymatic activity, whereas phosphorylation of Ser975 in the 
juxtamembrane segment downregulates the kinase activity. The carboxy-terminal tail includes two 
critical tyrosines (Tyr1349 and Tyr1356) that, once phosphorylated, act as a promiscuous docking site 
for the recruitment of several transducers and adaptors. 
[Adapted from the following article: Comoglio, PM., Giordano, S. Trusolino, L. (2008) Drug 
development of MET inhibitors: targeting oncogene addiction and expedience. Nat Rev Drug Discov. 
7:504-16.] 
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The MET ligand: Hepatocyte Growth Factor (HGF). 
Hepatocyte growth factor is the ligand of the MET tyrosine kinase. This growth factor 
was independently discovered by two groups who identified it through different 
experimental approaches:  the first one characterized it as a potent motility factor and 
thus named it as “scatter factor”; the second one identified the factor for its ability to 
promote growth of hepatocytes,  hence the name of hepatocyte growth factor 
(Naldini,L. et al., 1991; Uehara, Y. et al., 1995). These two factors, later, turned out to 
be the same molecule (Schmidt, C. et al., 1995; Huh, C. G. et al., 2004), which is 
usually known as HGF.  
HGF is secreted by mesenchymal cells and acts mainly on cells of epithelial origin. It 
is secreted as a single inactive polypeptide and it is cleaved by serine proteases into a 
69-kDa alpha-chain and a 34-kDa beta-chain. A disulfide bond between the alpha and 
beta chains is present in the active, heterodimeric molecule. The protein belongs to the 
plasminogen subfamily of S1 peptidases but it has no detectable protease activity.  
 
MET and the Invasive Growth program. 
MET activation evokes pleiotropic biological responses, both in vitro and in vivo, 
often referred to as “invasive growth”. This is a complex genetic program, specifically 
induced by the Scatter Factor Receptors MET and Ron. It consists in a series of 
obligate rate-limiting steps physiologically occurring during embryogenesis and tissue 
repairing. In the first step of this process, cells acquire the ability to dissociate from 
their neighbors, by breaking intercellular adherent junctions (“scattering”) and then 
leave their original environment and reach the circulation (“directional migration” 
and “invasion”). Cell survival in the bloodstream is facilitated by MET-induced 
protection from apoptosis and ability to transiently grow in an anchorage-independent 
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manner. Finally, cells extravasate, face the new environment, proliferate and 
eventually undergo terminal differentiation (Giordano, S. et al., 1993). 
In vivo, MET is expressed in epithelial cells of many organs (Sonnenberg,E. et al., 
1993)  ; under physiologic conditions MET contributes to the establishment of normal 
tissue patterning and to the onset and persistence of normal organ architecture. In fact, 
during embryogenesis, the invasive growth process is an essential step that ensures the 
correct structural tissue organization; in adulthood , when the architectural tissue 
organization is already well established, MET activity becomes dispensable but it is 
still required when tissues are damaged and cells have to reacquire the ability to 
dissociate, migrate and repair the regenerating tissues (Uehara, Y. et al., 1995; 
Schmidt, C. et al., 1995; Huh, C. G. et al., 2004). 
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Fig 1.2  
After ligand-induced dimerization, the tyrosine kinase domain (purple) phosphorylates two key 
tyrosines included in a specific four-residue sequence (red) in the receptor cytoplasmic tail. These 
generate a docking site with specificity for the indicated signal transducers. The specificity of the 
biological response (invasive growth) results from the receptor's individual signaling profile originated 
by combining the nature of the pathways with their intensity, duration and synchrony. Moreover, the 
receptor phosphorylates signal amplifiers at multiple sites, lowering the threshold for the response.  
[From the following article:  Comoglio, PM. (2001) Pathway specificity for Met signalling. Nat Cell 
Biol. 3:E161-2.] 
 
MET and Cancer. 
In transformed tissues, deregulation of the invasive growth program is responsible for 
cancer progression and metastasis. Constitutive MET activation forces neoplastic cells 
to disaggregate from the tumor mass, erode basement membranes, infiltrate stromal 
matrices, and eventually colonize new territories to form metastases, somehow 
recapitulating the physiological invasive growth program (Trusolino,L. and 
Comoglio,P.M., 2002). 
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Fig 1.3  
 
The invasive growth program under physiological and pathological conditions. In both settings, 
invasive growth results from analogous biological processes - cell-cell dissociation and migration, cell 
proliferation and survival - but the endpoints are different. Normal cells exploit invasive growth to 
colonize new territories and build polarized three-dimensional structures, thus forming the parenchymal 
architecture of several organs. Cancer cells implement this program aberrantly to infiltrate the adjacent 
surroundings and form metastases. 
[From the following article:  Comoglio, P.M. and Trusolino, L. (2002) Series Introduction: Invasive 
growth: from development to metastasis. J Clin Invest. 109: 857–862.]  
 
Indeed, data produced by many laboratories provide compelling evidence that HGF-
MET signaling plays an important role in the development and malignant progression 
of tumors. First, cell lines that ectopically overexpress MET or HGF become 
tumorigenic and metastatic in nude mice, while MET down-regulation decreases their 
tumorigenic potential; second, MET or HGF transgenic mice (Wang,R. et al., 2001; 
Takayama,H. et al., 1997) develop metastatic tumors; third, aberrant MET expression 
(usually overexpression) has been found in many kinds of solid tumors and correlates 
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with poor prognosis (Birchmeier,C. et al., 2003). Furthermore, MET signaling is 
involved in the regulation of tumor angiogenesis, either directly, through the pro-
angiogenic activity of HGF that induces the formation of new vessels and the 
sprouting of the pre-existing ones, or indirectly, through the regulated secretion of 
angiogenic factors, such as VEGFA (Gille, J., et al. 1998), interleukin-8 (IL-8) and 
trombospondin-1 (Rosen, E.M. et al., 1993; Zhang, Y.W. et. al, 2003). Moreover, not 
only endothelial cells, but also macrophages (Galimi, F. et al., 2001) and other 
leucocytes (Skibinski, G., 2003) express MET and it has been shown that activation of 
this receptor in these cells can contribute to tumor growth and metastasis formation. 
Several experimental evidences have indeed demonstrated that therapeutic MET 
targeting also impairs the function of inflammatory cells, interfering with the pro-
tumorigenic role of the tumor microenvironment (Zhang, Y. W. et.al, 2003). 
Nowadays, several mutations were founded in the MET gene (Fig 1.4). 
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Fig 1.4 
 
Mutations of MET in human solid tumors. MET receptor is shown in the schematic diagram 
highlighting different functional domains of the receptor: extracellular semaphorin (Sema) domain, PSI 
domain, the four IPT-repeats, transmembrane (TM) domain, juxtamembrane (JM) domain and 
cytoplasmic tyrosine kinase (TK) domain. The MET mutations identified in different human solid 
cancers are represented in the top. Summary of various mutations of MET previously reported in 
human solid cancers, including renal cell carcinomas (both sporadic and hereditary), gastric carcinoma, 
hepatocellular carcinoma, glioma, squamous cell carcinoma of the head and neck, SCLC, NSCLC, 
mesothelioma and melanoma, are shown in the bottom for comparison.  
[From: Ma PC, et al. (2008) Expression and mutational analysis of MET in human solid cancers. 
Genes Chromosomes Cancer. 47:1025-37.] 
 
The main proof that MET is directly involved in tumorigenesis came from the 
identification of germ-line activating mutations in patients with hereditary papillary 
renal carcinoma (HPRC) (Schmidt, L. et al., 1997). 
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Schmidt et al. sequencing the MET gene from affected members of HPRC families 
and from tumor samples of patients with sporadic papillary carcinoma, identified nine 
different mutations (referred to as METPRC mutations) that result in amino acid 
substitutions in the kinase domain of the receptor. Three of these mutations (D1228N, 
D1228H, and M1250T) are located in codons homologous to those mutated in the 
tyrosine kinase receptors Kit and Ret. Mutated Kit alleles are found in patients with 
mastocytosis and acute myeloid leukemia of M2 subtype (Piao, X., Bernstein, A., 
1996; Beghini, A. et al., 1998) and missense mutations in Ret are associated with 
multiple endocrine neoplasia type 2B (MEN2B) (Hofstra, R. M. et al., 1994). This 
suggests that alteration of these residues is a critical event in deregulating tyrosine 
kinase receptors. 
 
Fig 1.5 
Schematic picture of the MET receptor structure. In blue is represented the MET intracellular tyrosine 
kinase domain, and the two tyrosines in the C-terminal region -that are required for interactions with a 
number of effector proteins- were indicated (P). The orange brace bracket recapitulate the list of 
METPRC mutations of the kinase domain (KD) found in HPRC. KD: kinase domain; P: phosphorylation 
site; S▪S: disulfide bond. 
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Mechanisms of MET activation in cancer. 
MET activation in human tumors can be induced through different mechanisms: 
 
1) MET overexpression. 
Overexpression is the most frequent alteration in human tumors. Overexpressed 
receptors undergo spontaneous dimerization and subsequent activation, even in the 
absence of ligand. Increased MET expression can be due to: i) MET gene 
amplification, most common in colorectal tumors (Birchmeier et al., 2003), in 21% of 
lung cancers become resistant to EGFR inhibitors (Bean et al., 2007), gastric cancers, 
where 10–20% of all primary tumors and up to 40% of the scirrhous histological 
subtype have increased MET gene copy numbers (Sakakura et al., 1999; Kuniyasu et 
al., 1992). 
  Recently, it has been shown that gastric and lung cancer cell lines harboring 
amplification of the MET locus are addicted to the constitutive activity of this 
receptor for their growth (Corso et al., 2008; Lutterbach et al., 2007; Smolen et al., 
2006). (ii) Enhanced MET transcription, induced by other oncogenes, such as Ras, 
Ret and Ets or transcription factors such as MACC1 (Stein,U. et al., 2009). (iii) 
Hypoxia-activated transcription, leading to higher amounts of receptor that 
hypersensitize the cells to HGF and promote tumor invasion (Pennacchietti,S. et al. 
2003), (iv)  loss of negative regulators, like  microRNAs (miRNAs), is It is known 
that miRNAs play a role in human cancers where they can act either as oncogenes, 
down-regulating tumor suppressor genes, or as onco-suppressors, targeting molecules 
critically involved in promotion of tumor growth. Regarding the interplay between 
MET and miRNAs, Migliore C. et al. have identified three miRNAs (miR-34b, miR-
34c, and miR-199a*) that negatively regulate MET expression (Migliore  et al., 2008). 
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2) MET structural alterations. 
Sequencing the MET gene from affected members of HPRC families led to the 
identification of missense point mutations in the receptor kinase domain that have 
been shown to be responsible for this hereditary form of cancer. The same and other 
point mutations in the intracellular portion of the receptor have been identified also in 
sporadic occurring tumors, like childhood hepatocellular carcinomas, sporadic 
papillary renal carcinomas, gastric carcinomas (Birchmeier, C. et al., 2003)  and head 
and neck squamous cell carcinomas. In this last case, it has been shown that these 
mutations are selected during the metastatic spread and confer invasive properties to 
expressing cells (Nilkovitch-Miagkova, A. and Zbar, B., 2002). In vitro studies have 
proven what has been observed in human cancers (Soman, N.R. et al., 1991). 
 MET activation can originate also from abnormal post-translational processing, as 
shown in cell lines with a defect in furine activity. In fact, lack of cleavage of the 
single chain MET precursor and failure to originate the two-chains mature 
heterodimer result in a constitutively active molecule (Nilkovitch-Miagkova,A. and 
Zbar,B., 2002).   
Increased MET activation can also derive from impaired receptor down-regulation. 
Mutations that prevent binding of the Cbl ubiquitin ligase, responsible for MET 
ubiquitinylation and endocytosis, lead to increased amount of receptors expressed at 
the cell surface and to enhanced signal transduction (Trusolino,L. and Comoglio,P.M., 
2002). Finally, naturally truncated and active MET receptors have been detected in 
malignant human muscoloskeletal tumors (Nilkovitch-Miagkova,A. and Zbar,B., 
2002).   
 
3) HGF-dependent paracrine/autocrine activation. 
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MET can be activated by its ligand, HGF, either in a paracrine or an autocrine 
manner. Autocrine activation occurs when tumor cells aberrantly express both HGF 
and its receptor, as shown in osteosarcomas and rhabdomyosarcomas, gliomas and 
carcinomas of thyroid, breast, and lung (Birchmeier,C. et al., 2003).  
4)HGF-independent mechanisms.  
MET activation can happen in a HGF-independent manner through its transactivation 
via other membrane receptors, including adhesive receptors, like CD44 and integrins 
(Trusolino, L., et al. 2001; Van, de Wetering et al. 1999), and signal transducing 
receptors, such as Ron, EGF receptor family members, FAS and B Plexins (Kruger, 
R. P., et al., 2005; Giordano, S. et al., 2002). It is interesting to note that all these 
receptors are individually believed to be involved in cancer progression. 
 
On these bases, MET is considered an important target in anti-cancer therapy with a 
possible anti-metastatic potential.  
 
Targeting MET. 
In recent times, molecules targeting MET reached the access to clinical trials. Most of 
them are small molecules tyrosine kinase inhibitors, while few are biological 
antagonists and monoclonal antibodies targeting either the ligand or the receptor (Fig 
1.6). 
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Fig 1.6 
Schematic representation of the structures of human c-MET and its potential signaling inhibition using 
various candidate therapeutic agents.  
[Adapted from: Wang MH, et al. (2010) Potential therapeutics specific to c-MET/RON receptor 
tyrosine kinases for molecular targeting in cancer therapy. Acta Pharmacol Sin. 31:1181-8.]  
 
1) MET/HGF competitors. 
The first attempts to interfere with cancer progression by targeting the HGF/MET 
system came in the late 1990s and aimed at interfering with HGF binding to MET, 
through the use of antagonistic compounds (‘competitors’). 
One of the most promising competitors is NK4, a variant of HGF comprising only the 
four-kringles of the α chain; NK4 binds to MET without inducing receptor activation 
and thus behaves as a full antagonist (Date, K., et al., 1997). Its major limit relies in its 
inability to interfere with the development of tumors in which MET is activated in a 
HGF-independent manner. 
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A chimeric factor containing selected domains of HGF and MSP and able to signal 
through MET/Ron heterodimers was proven to be able to dissociate the trophic 
properties of HGF, such as proliferation and protection against apoptosis, from its 
pro-invasive ability. This opened the possibility of exploiting some ‘favorable’ effects 
of HGF to reduce, for example, chemotherapy-related cytotoxicity (Michieli, P. et al., 
2002).  
Recently, it has been shown that a mutated and uncleavable form of pro-HGF (HGF is 
first produced as a single, inactive precursor that is then cleaved in the two-chains 
mature form) obtained through a single amino acid substitution that prevents the 
cleavage of the single chain precursor in the mature form, can both displace HGF 
from MET and competitively inhibit the proteolytic activation of the endogenous pro-
HGF (Mazzone, M. et al., 2004).  
Another molecule with therapeutic potential is a soluble form of the MET 
extracellular portion (the so-called decoy-MET), a recombinant protein corresponding 
to the entire extracellular domain of MET. This molecule acts both on MET and HGF, 
as it blocks receptor dimerization and sequesters the circulating HGF (Michieli, P. et 
al., 2004). 
 
2) Monoclonal antibodies. 
Monoclonal antibodies are currently used to target other RTKs in cancer and are 
providing good therapeutic results. The best known examples, already approved by 
FDA, are Cetuximab (against EGFR) in head and neck and colorectal cancer, 
Trastuzumab (against HER-2) in locally advanced and metastatic breast cancer and 
Bevacizumab (against VEGF) in metastatic colon cancer and non-small-lung cancer 
(Barni, S., et al., 2007; Rocha-Lima, C.M. et al. 2007). It is important to underline that 
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monoclonal antibodies can interfere with RTKs’ activity either targeting the receptor 
(Cetuximab or Trastuzumab) or the ligand (Bevacizumab). 
Compared to the use of TKIs, one advantage of the monoclonal antibodies is  the high 
target specificity. In addition, some antibodies may elicit immune responses such as 
antibody-dependent cell-mediated cytotoxicity and complement-dependent 
cytotoxicity, which offer different tumor-killing mechanisms in addition to direct 
inhibition of the target.  
Like the c-MET TKIs, the antibodies have also been evaluated preclinically and 
demonstrated significant antitumor activity in HGF/c-MET-dependent tumor models, 
with good tolerability. 
Concerning the MET–HGF system, promising results have been obtained both with 
anti-HGF (one of them has just entered the first phase II clinical trial), and anti-MET 
antibodies. 
Recently, a panel of fully human monoclonal antibodies that bind to and neutralize 
human HGF has been developed (Burgess, T. et al., 2006). Kim and colleagues 
identified another monoclonal antibody, L2G7, active not only in vitro, but also able 
to interfere with tumor growth and to induce tumor regression in mouse models (Kim, 
K. J. et al. 2006).  
The potential use of mAbs targeting MET in human cancer therapy induced the 
production of a growing number of these molecules. As bivalent antibodies exhibited 
both agonistic and antagonistic activity towards the receptor, allowing a partial 
activation of MET downstream pathways (Christensen, J. G., et al. 2005), one 
monovalent antibody (Fab), named 5D5, was engineered to inhibit HGF-dependent 
MET activation (Martens, T. et al., 2006).  
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Finally, our group identified a mAb, named DN30, that efficiently down-regulates 
MET receptor. This specific mAb exploits its effect in inhibiting HGFR signaling by a 
dual mechanism: on one hand it reduces the number of receptor molecules on the cell 
surface; on the other hand it promotes the release of a decoy HGFR (Petrelli, A. et al., 
2006)  which is endowed with a dominant negative activity. Another important 
observation is that the inhibitory mechanism activated by this mAb does not require 
HGFR tyrosine kinase activity. This feature represents a relevant advantage in the 
perspective of a therapeutic approach, because, in clinical practice, it is frequent to 
combine different drugs to improve the effect on the target molecule. In the case of 
HGFR, it would thus be possible to combine kinase inhibitors with the mAb, allowing 
the contemporary action on both HGFR activation and receptor levels; this  is likely to 
enhance the therapeutic efficacy of target therapy in HGFR-overexpressing tumors, 
with the aim of interfering with both tumor growth and the acquisition of an invasive–
metastatic phenotype. 
 
3) Small molecules. 
From a pharmacological point of view, the most promising tools for cancer therapy 
are believed to be the competitors for the ATP binding site of the receptor, the so-
called ‘small kinase inhibitors’ or ‘small molecules’. The reason for the increasing 
interest in the development of these compounds is their good efficacy in clinics (for 
example Gleevec, targeting c-kit and BCR-ABL, Iressa and Tarceva, targeting EGFR 
and Sorafenib, targeting several RTKs) and to their ability to inhibit receptor 
activation due not only to ligand binding but also to over-expression or interaction 
with co-receptors. This last issue is of particular interest dealing with MET, as 
activation due to receptor over-expression is quite frequent in human tumors 
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(Desiderio, M. A., 2007). Moreover, as already discussed, several data strongly 
suggest that MET cross-talk with other membrane receptors may lead to its activation 
in the absence of the ligand For all these reasons, it is important to develop 
compounds able to efficiently switch off MET signal. Despite the potentiality of small 
molecules in cancer therapy, it must be taken into consideration that if, on one hand, 
these molecules are very effective and promising, on the other hand, they may create 
problems for side-effects because ATP analogues are likely not absolutely specific for 
a given tyrosine kinase, and thus, toxicity is a big concern. 
Initial attempts to identify MET-ATP binding site competitors brought to the 
identification and characterization of K252a, a Staurosporine analogue, behaving as a 
broad spectrum kinase inhibitor (Morotti, A.,et al., 2002).  
Searching for more selective compounds, two new small-molecule inhibitors have 
been developed: SU11274 and PHA-665752. At nanomolar concentrations, they both 
strongly inhibit HGF-induced activation of MET in cultured cells and tumorigenicity 
in mouse models (Berthou, S. et al., 2004; Ma, P. C., et al., 2005). 
Recently, Zou and colleagues identified a new small-molecule inhibitor, named PF-
2341066: it is an orally available ATP-competitive compound selective for MET. In 
vivo, this compound showed a good tolerability and a dose-dependent anti-tumor 
activity (Zou, H. Y. et al., 2007).  
Agents that showed encouraging clinical benefit as well as acceptable safety profiles 
in early-stage trials have progressed rapidly in the clinic. These include ARQ197, 
XL184 and PF-2341066, all of which are currently being evaluated in Phase III trials 
(Table 1).  
A novel MET/RON inhibitor (Compound I, from Amgen) has been recently identified 
and characterized. This molecule specifically inhibits both the receptors belonging to 
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the same RTK family and prevents the activation of the invasive growth program in 
response to the interaction with the cognate ligands. Compound I showed specific 
anti-tumor activity in animal models known to be dependent on either MET or Ron 
activation  (Zhang Y, et al., 2007).  
Finally, an indirect approach to interfere with MET activity has been achieved using 
geldanamycin (GA), an anti-tumor drug that binds to and inhibits HSP90 chaperone 
activity by preventing proper folding and functioning of certain oncoproteins and, 
amongst them, MET (Xie, Q. et al., 2005). 
 
4) Clinical trials. 
Recently, some molecules targeting MET reached the access to clinical trials: they all 
share low levels of toxicity but further investigations are required to optimise the 
clinical settings (Table 1). 
 
Table 1. c-MET pathway inhibitors in development.  
Agent Developer Comments   
Selective TKIs  
ARQ197 ArQule/Daiichi 
Sankyo/Kyowa Hakko 
Kirin 
c-MET enzyme K i: 355 nM; cellular IC50: 300 – 
1000 nM 
Phase III (NSCLC), Phase II (CRC, gastric, HCC, 
germ cell and MiT tumors) 
Clinical activity: PR and SD reported in lung, 
neuroendocrine, prostate, testicular, gastric, 
colorectal, ovarian, pancreatic and renal cancers 
  
JNJ38877605 Johnson & Johnson c-MET enzyme IC50: 4 nM; cellular IC50: 50 nM 
Phase I (advanced solid tumors): completed 
  
INCB28060 Novartis/Incyte c-MET enzyme IC50: 0.13 nM; cellular IC50: 1 nM 
Phase I (advanced tumors) 
  
EMD1214063  
EMD1204831 
EMD Serono c-MET enzyme IC50: 1 nM; cellular IC50: 1 – 6 nM 
c-MET enzyme IC50: 12 nM; cellular IC50: 15 nM 
Phase I (advanced solid tumors) 
  
AMG337 Amgen c-MET enzyme and cellular IC50: unknown 
Phase I (advanced solid tumors) 
  
Non-selective TKIs     
PF-2341066 (crizotinib) Pfizer c-MET enzyme IC50: 4 nM; cellular IC50: 11 – 13 
nM  
Also active against ALK: 2-fold less potent 
Phase III (ALK-altered NSCLC), Phase I–II (lung, 
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Table 1. c-MET pathway inhibitors in development.  
Agent Developer Comments   
ALCL and other tumors) 
Clinical activity: PR and SD reported in NSCLC and 
inflammatory myofibroblastic sarcoma patients with 
ALK rearrangement 
XL184 (cabozantinib) Exelixis c-MET enzyme IC50: 1.8 nM; cellular IC50: 8 nM 
Also active against VEGFR, RET, KIT, FLT3 and 
TIE2  
Phase III (medullary thyroid cancer), 
Phase II (glioblastoma/astrocytoma, NSCLC and 
RDT design in nine tumor types: breast, gastric, 
NSCLC, ovarian, pancreatic, prostate, SCLC, liver 
and melanoma) 
Clinical activity: PR and SD reported in various 
tumors including thyroid, carcinoid, neuroendocrine, 
parotid, appendiceal, liver, colorectal, renal, 
melanoma, mesothelioma, renal, liver, lung, 
glioblastoma and cutaneous T-cell lymphoma 
     
GSK1363089/ XL880 
(foretinib) 
GlaxoSmithKline c-MET enzyme IC50: 0.4 nM; cellular IC50: 23 nM 
Also active against VEGFR, AXL, PDGFR, KIT, 
FLT3 and TIE2 
Phase II (breast, NSCLC, papillary renal, gastric and 
head and neck), Phase I (liver) 
Clinical activity: PR and SD reported in thyroid, 
renal, colorectal, carcinoid, melanoma, 
nasopharyngeal, urethral, ovarian, mesothelioma and 
gastric cancers 
     
MGCD265 Methylgene c-MET enzyme IC50: 24 nM; cellular IC50: 40 nM 
Also active against RON, VEGFR1/2/3 and TIE2 
Phase II (NSCLC), Phase I (advanced tumors) 
     
E7050 Eisai c-MET enzyme IC50: 14 nM; cellular IC50: 6 – 37 
nM  
Also active against VEGFR2 
Phase II (HCC), Phase I (advanced solid tumors) 
     
AMG208 Amgen c-MET enzyme IC50: 4 nM; cellular IC50: 10 – 100 
nM  
Also active against RON 
Phase I (various tumors) 
     
MP470 SuperGen c-MET enzyme and cellular IC50: unknown 
Also active against KIT, PDGFR, FLT3, RET and 
RAD51  
Phase I (various tumors): completed 
Clinical activity: PR and SD reported in lung cancer 
     
BMS-777607 Bristol-Myers Squibb c-MET enzyme IC50: 3.9 nM; cellular IC50: 20 – 160 
nM  
Also active against Ron, AXL, TYRO3 and MER 
Phase I–II (advanced solid tumors): completed 
     
MK-2461 Merck c-MET enzyme IC50: 2.5 nM; cellular IC50: 26 – 900 
nM  
Also active against RON, FLT1, 3 and 4, and FGFR1, 
2 and 3 
Phase I–II (various tumors): completed 
     
Therapeutic Abs     
MetMAb (PRO143966) Genentech/Roche Humanized anti-human c-MET monovalent antibody 
Phase II (NSCLC and triple negative breast cancer) 
Clinical activity: CR and SD reported in lung, gastric 
and melanoma cancers 
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Table 1. c-MET pathway inhibitors in development.  
Agent Developer Comments   
AMG102/(rilotumumab) Amgen Humanized anti-human HGF IgG2 
Phase II (SCLC, NSCLC, CRC, prostate, glioma, 
RCC, gastric or esophagogastric junction 
adenocarcinoma, mesothelioma and gynecologic 
tumors)  
Clinical activity: PR and SD reported in glioblastoma 
and other tumors 
    
AV-299 Aveo Humanized anti-human HGF antibody 
Phase II (lung), Phase I (advanced solid tumors, 
lymphomas and MM) 
    
 
 
Mechanisms of resistance to tyrosine kinase inhibitors. 
In the field of acquired resistance to kinase inhibitors, three major mechanisms of 
resistance have begun to emerge: (i) genetic alterations of the target, such as gene 
amplifications that leads to receptor overexpression and thus render the amount of 
available drug not sufficient to block the target; (ii) mutations in the target kinase  that 
abrogate the inhibitory action of the drug [e.g., T790M in epidermal growth factor 
receptor (EGFR) and T315I in ABL]; (iii) activation of signaling pathways that 
bypass the continued requirement for the original target; (iv) constitutive activation of 
downstream transducers. 
Among the most common mechanisms of resistance, genetic modifications include -
but are not limited- to: point mutations, deletion and amplification of genomic areas. 
As previously reported, unequivocal evidence that implicates MET in human cancer is 
provided by the activating mutations that have been discovered in both sporadic and 
inherited forms of human renal papillary carcinomas (Schmidt, L. et al., 1997). 
Activating mutations have also been described in sporadic tumors such as childhood 
hepatocellular carcinomas (Park, W. S. et al., 1999), sporadic papillary renal 
carcinomas (Schmidt, L. et al., 1997), gastric carcinomas (Lee, J. H. et al., 2000), lung 
carcinomas (Kong-Beltran, M. et al., 2006)  and head and neck squamous cell 
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carcinomas (Di Renzo, M. F. et al., 2000). The table 2 recapitulate that such 
mutations, which alter sequences within the kinase domain, have also been found in a 
large types of cancer and metastatic lesions.  
 
 
 
Tab 2  
Hepatocyte growth factor/scatter factor, MET and cancer references. 
 
[From the following article: Birchmeier, C. et al., (2003) Met, metastasis, motility and more. Nature 
Reviews Molecular Cell Biology 4, 915-925] 
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THE SCIENTIFIC PROBLEM  
AND THE AIM OF THE WORK 
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Targeted cancer therapies are based on the use of drugs that block the growth and 
spread of cancer by interfering with specific molecules involved in tumor growth and 
progression. By focusing on molecular and cellular changes that are specific to 
cancer, targeted cancer therapies may be more effective than other types of treatment, 
including chemotherapy and radiotherapy, and less harmful to normal cells. The 
development of targeted therapies, therefore, requires the identification of good 
targets: in other words, targets that are known to play a key role in cancer cell growth 
and survival. In cancers driven by a dominant oncogene, targeted therapies have led to 
remarkable improvements in response and survival, whereas in others the outcome 
has been more modest. 
Once a target has been identified, a therapy must be developed; most targeted 
therapies are either small-molecule drugs or monoclonal antibodies. Small-molecule 
drugs are typically able to diffuse into cells and can act on targets that are found 
inside the cell. Most monoclonal antibodies cannot penetrate the cell plasma 
membrane and are directed against targets that are outside the cell or on the cell 
surface.  
Many targeted cancer therapies have been approved for the treatment of specific types 
of cancer, others are being studied in clinical trials, and many more are in preclinical 
testing.  
Unfortunately, many patient’s tumor types are refractory to targeted therapies 
(intrinsic resistance). Moreover, even if an initial response to targeted therapies is 
obtained, the vast majority of tumors subsequently become refractory (i.e., acquired 
resistance) and patients eventually progress.  In the majority of cases this is caused by 
expansion of clones containing mutated forms of the target, which confer insensitivity 
to the drug.  
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In addition, multiple factors including pharmacokinetics issues, such as suboptimal 
drug delivery, further contribute to resistance formation. Loss of target dependence 
due to the activation of parallel signaling pathways has also been reported as cause for 
acquired drug insensitivity.  
Taking together, recent basic and clinical research is  trying to improve the efficacy of 
targeted therapies by developing new generations of rationally designed targeted 
agents, and translating this information to the clinic to select patients for appropriate 
therapy. 
However, one key aspect to improve  the potential of targeted therapies is, first of all, 
a better understanding the intrinsic or acquired resistance mechanisms that limit their 
efficacy. 
 
In this scenario, the aim of my PhD project was to evaluate the activity of  some 
available  anti-MET therapies (small molecules and monoclonal antibody) targeting 
the MET receptor harboring mutations in the kinase domain and, if some mutants 
were insensitive to the inhibitor, to investigate the mechanisms responsible for 
resistance. Then, I aimed to evaluate  if the  mutants resistant to small kinase 
inhibitors are still sensitive to other chemicals inhibitors or monoclonal antibodies 
against MET. Finally, since the anti-MET therapies are ongoing in NSCLC patients, I 
also screened surgically resected lung cancers  to identify activating point mutations  
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RESULTS 
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Evaluation of sensitivity of MET PRC mutants to the MET TKI inhibitor PHA-
665752 
As previously shown, sequencing the MET gene from affected members of HPRC 
families and from tumor samples of patients with sporadic papillary carcinoma 
allowed the identification of nine different MET mutations (referred to as METPRC 
mutations) that result in amino acid substitutions in the protein. All METPRC mutations 
belong to the “gain of function” type and lead to constitutive activation of the protein 
(see Tab 3.1). This results in constitutive tyrosine phosphorylation of the receptor that 
can be experimentally used as a read-out of its activation. 
 
MISSENSE MUTATION 
(AMINOACID 
SUBSTITUTION) 
REFERENCE 
NUMBER OF THE 
MUTANT 
M1131T MET PRC1 
V1188L MET PRC 2 
L1195V MET PRC 3 
Y1230C MET PRC 4 
Y1230H MET PRC 5 
V1220I MET PRC 6 
D1228H MET PRC 7 
D1228N MET PRC 8 
M1250T MET PRC 9 
  
Tab 3.1 
Schematic summary of all METPRC mutants: aminoacid substitution and corresponding reference 
number of the mutant (chosen to make the reading easier). 
 
To evaluate if METPRC mutants are sensitive or resistant to the MET small kinase 
inhibitor PHA-665752, we first transiently transfected MET wt and all the METPRC 
mutants in the COS-7 cell line, derived from the kidney of African green monkey.  
- 32 - 
 
This cell line is a fibroblast-like cell line established from CV-1 simian cells which 
were transformed by an origin-defective mutant of SV40 encoding for wild-type T-
antigen. This cell line is suitable for high efficient transient transfection (Gluzman, Y., 
1981 ). All the mutants cloned in the plasmidic mammalian expression vector pCEV 
29.1 were available in the laboratory (Giordano, S., et al. 2000). 
 
A 
 
 
 
 
 
B 
 
 
Fig 3.1  
(A) The plasmidic construct pCEV29.1. Wild-type and mutant MET cDNAs were cloned into the 
pCEV29.1 expression vector (Giordano, S., et al. 2000) and the quality of the plasmidic DNA was 
validated by agarose gel electrophoresis (B).  
 
 
 
 
 
pCEV 29.1 
(10 kb) 
MET (4224 bp) 
 
WT    1     2    3     4    5     6      7    8     9 
M-MLV 
LTR 
amp 
SV-40 polyA 
neo 
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Transfections were performed by the DEAE-dextran technique. Briefly, DEAE-
dextran transfection is one of the oldest chemical, nonviral methods developed to 
transfer RNA or DNA to cultured mammalian cells. The standard transfection 
protocol involves pretreatment of cells with chloroquine, followed by exposure of the 
cells to a DEAE-dextran and DNA solution. Sixteen hours after transfection, cells 
were treated with the small molecule tyrosine kinase inhibitor PHA-665752 [250] nM. 
Twenty four hours later, cells were lysed with boiling Laemmli buffer (Laemmli, 
UK., 1970), proteins were quantified by Pierce BCA (bicinchoninic acid) Protein 
Assays and analyzed by western blot (WB). As shown in Fig 3.2, we observed that, 
while phoshorylation of MET wt and of some METPRC mutants (i.e. M1130T, 
V1188L, V1220I, M1250T) was inhibited in presence of PHA-665752, other mutants 
(namely L1195V, Y1230C, Y1230H, D1228H, D1228N) were still phosphorylated. 
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A 
 
 
B 
 
 
 
Fig 3.2 
 
Equal amounts of pCEV 29.1 containing the cDNA of MET wt or of the different MET PRC mutants 
were transfected in COS-7 cells with DEAE-dextran procedure. After transfection, cells were untreated 
(A) or treated (B) with the ATP-competitive tyrosine kinase inhibitor PHA-665752 [250] nM. After 24 
hours of treatment, cells were washed with phosphate-buffer saline (PBS) and lysed with Laemmli 
buffer. Proteins were quantified using the BCA Protein Assay Kit (Pierce, Rockford, IL) and analysed 
by Western Blots. As shown, blots probed with anti-phospho MET antibodies (directed against the 
phosphorylated tyrosines 1349/1356) showed that some METPRC mutants (the red ones namely 
L1195V, Y1230C, Y1230H, D1228H, D1228N, operatively defined as mutants 3, 4, 5, 7 and 8 
respectively) remained phosphorylated, and thus active, also in presence of the inhibitor. GTL16 cells, 
derived from a gastric carcinoma, over-expressing a constitutively phosphorylated receptor, were used 
as positive control for the TKI and antibody functionality. 
 
 WT       1         2        3        4         5         6         7        8         9 
 WT       1         2        3          4         5         6         7        8         9 
Anti MET  
Anti p-MET  
1349-1356 
Anti MET  
Anti p-MET  
1349-1356 
PHA-665752 [250]nM 
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In order to assess whether the lack of receptor inhibition was a dose-dependent effect 
or a real inability to respond to the drug treatment, we repeated the same experiments 
using a dose of PHA-665752 ten times higher than the IC50. As shown in Fig 3.3, 
tyrosine phosphorylation of the MET mutants 4, 5, 7 and 8 was not inhibited even at 
these high doses. MET mutant 3 was only partially inhibited, suggesting the existence 
of a different mechanism of drug resistance.  
 
A 
          PHA-665752 [250] nM                     
 
 
 
B 
        PHA-665752 [500] nM                      
 
 
Fig 3.3  
COS-7 cells transiently transfected with equal amounts of pCEV 29.1 containing the cDNA of MET wt 
or the different METPRC mutants were treated with the PHA-665752 TKI at two different 
concentrations: [250] nM (A) and [500] nM (B). After 24 hrs of drug treatment, cells where lysed in 
boiling Laemmli buffer. WB analysis revealed that MET phosphorylation of the resistant mutants (the 
red ones numbers 3, 4, 5, 7, 8 respectively) was persistent also at higher doses of TKI. 
 
PHA-665752 was identified as a small ATP-competitive molecule, inhibitor of the 
catalytic activity of c-MET kinase (Ki of 4 nM, IC50 of 9 nM). PHA-665752 also 
exhibited >50-fold selectivity for c-MET compared with a panel of diverse tyrosine 
Anti p-MET 1349-1356 
Anti p-MET 1349-1356  
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and serine-threonine kinases. In cellular studies, PHA-665752 potently inhibited 
HGF-stimulated and constitutive c-MET phosphorylation, as well as HGF and c-
MET-driven phenotypes such as cell growth (proliferation and survival), cell motility, 
invasion, and/or morphology of a variety of tumor cells (Christensen, JG., 2003). 
To evaluate if the inability to respond to PHA-665752 was shared also by other ATP-
competitive MET inhibitors, we treated COS-7 cells expressing the different mutants 
with another small molecule tyrosine kinase inhibitor, the JNJ-38877605.  
JNJ-38877605 is an orally bioavailable, highly specific MET inhibitor (selective over 
other 229 kinases tested). This agent inhibits c-MET with IC50 at 4 nmol/L and has a 
different chemical structure than PHA-665752 (see Fig 3.4). 
 
 
 
                         PHA-665752                                          JNJ-38877605 
 
Fig 3.4 
Chemical structure of the small molecules TKIs PHA-665752 and JNJ-38877605. 
 
As shown in Fig 3.5 all the mutants that were responsive to PHA-665752, were also 
responsive to JNJ-38877605, and mutants resistant to PHA-665752 remained active 
also in the presence of JNJ-38877605. 
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A 
 
 
 
 
 
B 
 
 
 
 
 
 
Fig 3.5 
COS-7 cells transiently transfected with MET cDNAs (WT or mutated), were treated with the small 
molecule TKI JNJ-38877605. WB analysis confirmed that mutants responsive to PHA-665752 were 
sensitive also to JNJ-38877605 (A) while mutants resistant to PHA-665752 were resistant also to JNJ-
38877605. GTL16 cells (A) were used as a positive control for the TKI inhibition and antibody 
detection. 
 
 
 
 
WT 
  0       250    500 
1 
          0       250      500 
2 
        0 ......250   500 
6 
     0      250      500 
9 
0         250    500 
3 
0       250    500 
4 
0    250   500 
5 
0         250       500 
7 
0         250      500 
8 
0         250    500 
Anti p-MET  
1349-1356 
Anti MET 
Anti MET  
JNJ nM 
JNJ nM 
GTL-16 
  0       250    500 
Anti p-MET  
1349-1356 
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Generation of stably transfected cell lines expressing the METPRC mutants  
As shown by Jeffers et al., MET receptors containing the different PRC point 
mutations display different abilities to induce transformation in NIH 3T3 fibroblasts 
(Jeffers M, et al., 1997). In fact, only mutations that affect residues located in the 
kinase activation loop efficiently transformed NIH 3T3 mouse fibroblasts (Fig 3.6). 
 
 
 
 
Fig 3.6 
Left part: Map of MET mutations found in Hereditary Papillary renal carcinomas. Schematic 
representation of functional domains of MET tyrosine kinase. The black box depicts the tyrosine kinase 
domain (KD), which can be subdivided into amino- and carboxyl-terminal lobes (N-L and C-L, 
respectively), separated by a large cleft referred to as the activation loop (AL). YY represents the 
receptor multifunctional docking site. Mutations found in PRCs are listed and the homology with 
residues mutated in RET and KIT receptors is indicated. 
Right part: Transforming ability of MET PRC mutants evaluated using the focus formation assay. Values 
reported represent the average of three independent experiments. 
[Data and pictures adapted from the following article: Giordano S. et al., Different point mutations 
in the met oncogene elicit distinct biological properties. FASEB J. 2000 Feb;14(2):399-406.] 
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Furthermore, the METPRC mutant endowed with the highest transforming ability 
(namely MET M1250T) also displayed the highest catalytic activity (Giordano, S. et 
al., 2000).  
In order to evaluate if the cells expressing the METPRC mutants display a different 
biological behavior in the presence or in the absence of PHA-665752, we aimed at 
generating stably transduced NIH 3T3 cells (that express very low levels of 
endogenous MET). We thus chose two representative METPRC mutants: METPRC 8 
(MET D1228N), resistant to PHA-665752, and METPRC 9 (MET M1250T), 
responsive to the drug treatment. 
To optimize the transduction efficiency, we decided to express the MET mutants in 
lentiviral vectors. We thus mutagenized the MET cDNA cloned in the pRLL2 
lentiviral vector, already available in the lab. The two PRC mutants were thus 
obtained performing an in vitro site-directed mutagenesis (Strategene’s QuickChange 
II XL Site-Directed Mutagenesis Kit) that allows to introduce site-specific mutations 
in the double-stranded plasmid pRLL2 containing the MET wild type cDNA. The 
obtained mutagenized cDNAs were validated by direct sequencing (Fig 3.7).  
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Fig 3.7 
Alignment between the MET wild type cDNA sequence and the METPRC mutants number 8 or 9. 
The point mutations are highlighted in red, the mutational analysis was performed using the Mutation 
Surveyor software, the represented alignment was obtained by the program “ClustalW Multiple 
Alignment” available in the web. 
 
To produce stably expressing cells, we used the lentivirus expression systems based 
on HIV-1 that are becoming very popular for gene delivery into host cells, because 
they offer many advantages over both traditional retroviruses and adenoviruses.  
First, we performed the multiplasmid transient transfection (the most widely used 
technique for generation of lentiviral vectors) with the traditional transient 
transfection protocol using 293T adherent cells and calcium phosphate/DNA co-
precipitation followed by ultracentrifugation (Vigna, E. and Naldini, L., 2000).  
The concentrated virus was quantified by the HIV-1 p24 Antigen ELISA (an enzyme 
linked immunoassay used to detect Human Immunodeficiency Virus Type 1 (HIV-1) 
p24 antigen in research specimens), and cell infections were performed using one 
g/ml of concentrated virus for 16 hours in the presence of polybrene (increasing 
virus adhesion to cells). 
Before performing biological assays, we confirmed the expression of the constructs in 
the stably transfected cells (Fig 3.8, bottom panel). We then carried out some 
biochemical experiments (response to HGF ligand and TKI inhibition) by stimulating 
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the cells with HGF (400U/ml for 15 minutes in serum free conditions), in the absence 
or in the presence of either PHA-665752 or JNJ-38877605. The results obtained with 
the two inhibitors were over imposable; figure 3.8 shows those obtained with JNJ-
38877605. As it can be observed, while both MET wt and METPRC 9 were inhibited 
by the TKI, METPRC 8 remained tyrosine phosphorylated, as previously observed in 
COS-7 cells (see Fig 3.5). 
 
 
 
          
 
Fig 3.8 
 Cells expressing the different constructs (MET WT or mutated), were stimulated with HGF (400U/ml 
for 15 min) in the absence (+) or in the presence (++) of JNJ-38877605 [500]nM. 
WB analysis showed that all cells expressing the MET cDNA responded to the ligand HGF; in 
presence of the TKI, the mutant number 8 was not inhibited (red circle) while cells expressing the 
responsive mutant 9 (blue circle) or MET WT lost their phosphorylation. NIH 3T3 cell line wt 
(untransduced) were used as negative control. A549 cells (an adenocarcinomic human alveolar basal 
epithelial cell line expressing an endogenous MET receptor quantitatively comparable to transduced 
NIH 3T3 cells) were used as positive control of the experiment and of anti p-MET antibody detection. 
Expression of the different constructs in stably transduced NIH 3T3 cells was previously evaluated 
using an anti MET antibody (bottom panel). 
 
A549 NIH 3T3 MET WT 
NT       +     ++ NT       +    ++ NT     +       ++ NT     +     ++ NT     +       ++ 
METPRC 8 METPRC 9 
  Anti p-MET  
1349-1356 
Anti MET  
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Biological properties of stably transfected cell lines expressing METPRC mutants  
To evaluate if the different behavior of the METPRC mutants could impact also the 
biological properties of the expressing cells, we decided to analyze some MET-
dependent activities such as cell migration and anchorage-independent growth. 
Concerning the biological responses, treatment with the TKI did not modify either 
receptor phosphorylation or MET-induced biological activities in cells expressing the 
resistant mutant D1228N (mutant 8): this was evident both in the soft agar assay 
(which evaluates the ability to grow in anchorage-independent conditions) and in 
migration/invasion assays, such as wound healing and transwell assays (see Fig 3.9). 
In details, colony formation and viability (both measured by Alamar Blue 
quantification) were not impaired in the presence of JNJ-38877605 in cells expressing 
the mutant number 8, while they were strongly decreased in those expressing MET wt 
or the mutant 9. Untransduced NIH 3T3 cells were used as negative control: as 
shown, these cells were not able to form colonies in soft agar.  
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Fig 3.9  
Anchorage-independent growth assays in soft agar and Alamar Blue quantification of cell viability. In 
the presence of the MET inhibitor, cells expressing either MET wt or the sensitive mutant number 9 
(blue lines) were severely impaired in their ability to grow in anchorage independent conditions, while 
cells expressing the resistant mutant 8 (red line) were unaffected. NIH 3T3 cell line wt (not expressing 
the MET gene) were used as negative control. The experiment was performed in presence of HGF (20 
ng/ml) and in presence or absence of JNJ-38877605. 
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We also performed in vitro biological assays to evaluate cell motility. In the invasion 
assay, cells were seeded in Transwell chamber, on the upper side of a porous 
polycarbonate membrane. The medium in both chambers was supplemented with low 
percentage of serum; the lower chamber was supplemented with  HGF (20 ng/ml) in 
presence or absence of JNJ-38877605. After 16 h, cells attached on the upper side of the 
membrane were mechanically removed. Cells that migrated to the lower side were fixed 
with gluataraldehyde and stained with crystal violet. Stained cells were photographed (see 
Fig. 3.10 A).  
To evaluate the ability to migrate and repair wounds, we performed a Wound Healing 
assay. This method mimics cell migration during wound healing in vivo. The basic 
steps involve creating manually a "wound" in a cell monolayer, capturing the images 
at the beginning and at regular intervals during cell migration and comparing the 
images to quantify the migration rate of the cells. As shown in Fig. 3.10 B, all cells 
increased their ability to migrate in presence of HGF (20 ng/ml) compared to the 
counterpart not treated (NT), but cells transfected with MET wt or with the responsive  
mutant 9 were not able to close the wound in presence of JNJ-38877605. Once again, the 
resistant mutant 8, showed an opposite response and its ability to migrate and close the 
wound was not impaired by the inhibitor. 
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A
 
B 
 
 
Fig 3.10 
Cells expressing MET WT or the mutants 8 and 9 were used to evaluate the ability to invade and migrate. 
The upper panel shows the results of a representative invasion assay in Transwells, in the lower part is 
represented the ability to migrate and repair the  wound by Wound Healing Assay. Both assays were 
performed using low percentage of serum, plus (experimental point named HGF) or minus (named NT) HGF 
(20 ng/ml), or in presence of HGF (20 ng/ml) plus JNJ-38877605 [500] nM.  
In both assays these two mutants showed an opposite response: while cells expressing MET wild type or the 
responsive mutant 9 (green rectangles) were inhibited, the resistant mutant 8 (yellow rectangles) was able to 
migrate also in the presence of inhibitor in both assays.  
HGF+ 
JNJ-38877605 
NT 
HGF 
  
MET WT METPRC 8 METPRC 9 
 
HGF+ 
JNJ-38877605 
NT 
HGF 
MET WT METPRC 8 METPRC 9 
   
- 46 - 
 
Analysis of lung tumors for the presence of MET mutations 
Nowadays pivotal studies in NSCLC (Non-Small Cell Lung Cancer) are ongoing, 
using specific chemical and biological anti-MET inhibitors; three of them (Met MAb, 
Crizotinib, ArQule-197) are in phase III clinical trials. The used drugs fall in two 
different categories: small kinase inhibitors (TKIs) and monoclonal antibodies 
(mAbs). They act with different mechanisms, since small TKIs interact with the 
receptor intracellular portion while mAbs bind to the extracellular domain. It is thus 
very likely that mutations present in diverse parts of the receptor can differentially 
impact on the ability to respond to either of the drugs. For these reasons and since 
METPRC mutations have been found not only in the germline of patients but also in 
sporadic tumors, we decided to analyze the sequence of the MET tyrosine kinase in 
human surgically resected lung cancers. 
As shown in the Tab 3.2, we collected resected lung tumors in collaboration with the 
Oncologic Hospital “A. Businco” of Cagliari (Dr. R. Versace) and Hospital 
“S.Giovanni Battista” of Turin (Prof. E. Ruffini), and we gathered the follow up of all 
patients (unfortunately not complete in all cases). The Classification of Malignant 
Tumors (TNM) is one of the most widely used staging systems. The TNM system is 
based on the extent of the tumor (T), the extent of spread to the lymph nodes (N), and 
the presence of distant metastases (M). A number is added to each letter to indicate 
the size or extent of the primary tumor and the extent of cancer spread. Tumor grade 
is a system used to classify cancer cells in terms of how abnormal they look under a 
microscope and how quickly the tumor is likely to grow and spread. Tumor grade 
should not be confused with the stage of a cancer. Cancer stage refers to the extent or 
severity of the cancer, based on factors such as the location of the primary tumor, 
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tumor size, number of tumors, and lymph node involvement (spread of cancer into 
lymph nodes). 
 
NUMBER OF 
SAMPLE 
 
ISTOLOGY 
 
STAGE 
 
GRADING 
 
 
T 
 
N 
 
M 
3118 Ca pavimentoso G2 
pT1aN0 
I A G2 T1 N0  
2279 Mts polmonari di ca retto 
G2 
IV G2    
119 adenocarcinoma con 
estese aree di necrosi 
IB G2 2 0 0 
280 carcinoma non a piccole 
cellule 
IIA  1 1 0 
285 carcinoma a grandi cellule 
con attività 
neuroendocrina 
IB  2 0 0 
286 Adenocarcinoma 
 
     
288 carcinoma epidermoide   1 0 0 
290 carcinoma bronchiolo 
alveolare mucinoso 
     
 
Tab 3.2 
List of samples used for mutational analysis of the MET gene and corresponding follow up. 
Classification is based on the Classification of Malignant Tumors (TNM), a cancer staging system that 
describes the extent of cancer in a patient’s body: T stands for tumor size and invasiveness.  The T 
number can range from T1 to T4.  T1 and T2 are differentiated primarily on size (<3 cm = T1, >3 cm = 
T2) and if the tumor is visible within a lobar bronchus (T2). T3 tumors involve the chest wall, but may 
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be resectable (operable). T4 tumors are not surgically resectable because they have invaded the 
mediastinum (the area and organs between the lungs) and involve the heart, great vessels, trachea or 
esophagus, or because they involve the pleura (lining of the lung) with a malignant pleural effusion 
(accumulation of fluid around the lining of the lung).  N stands for Nodal involvement (lymph nodes) 
and is staged from N1 to N3. M stands for the presence (1) or absence (0) of metastases (spread to a 
distant site). Grading (1–4) refers to the differentiation of the cancer cells (i.e. they are "low grade" if 
they appear similar to normal cells, and "high grade" if they appear poorly differentiated). About 
staging, Non-small cell lung carcinoma is usually staged from IA (best prognosis) to IV (worst 
prognosis).  
 
We purified total RNA from 16 samples (8 tumors and the corresponding peritumoral 
normal tissues). Upon RNA retrotranscription, we PCR amplified overlapping 
portions of the MET intracellular domain; amplified segments were then purified 
using the chemical method named Solid Phase Reversible Immobilization (SPRI) 
based on speed beads (Agencourt Ampure Xp Kit), and finally sequenced. (see Fig 
3.11). 
In one tumoral sample (but not in the corresponding peritumoral normal tissue) we 
found the presence of a missense mutation (Y1230H) resulting in aminoacid 
substitution (see Fig 3.12 A). The mutated aminoacid corresponds to Y1230H, which 
belongs to the METPRC mutants resistant to treatment with small kinase inhibitors. 
(Fig 3.12 B). Moreover, a very recent study (Qi J., et al., 2011) has shown that this 
mutation destabilizes the conformation of the MET TK domain and contributes to the 
development of acquired resistance to MET inhibitors.  
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B 
 
C 
                                                                                                 
 Fig 3.11 
RNA obtained from the 
different samples was retro-
transcribed; sequences 
comprising the TK domain 
of MET were amplified by 
PCR (A), purified with the 
Agencourt Ampure Xp Kit 
(B) and finally sequenced by 
Sanger’s method (C). 
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Fig 3.12 
The sequence analysis of MET tyrosine kinase domain in human resected lung cancer samples, was 
performed on RNA derived from both the tumors and corresponding normal tissues. In one sample 
(sample number 119 listed in the previous tab) the tumoral counterpart revealed the presence of the 
METPRC mutation Y1230H (the number 5) which was not present in the corresponding peritumoral 
tissue (A). This mutation, as previously reported, induces resistance to PHA-665752 . As shown the 
mutated receptor maintains a persistent phosphorylation also in presence of inhibitor, as highlighted by 
the blue circle in the lower part of the panel (B). 
 
 
 
Tumoral tissue 
Peritumoral 
tissue 
Y1230H 
PHA-665752 
[500] nM 
 
Anti p-MET  
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In silico structural analysis of the MET tyrosine kinase domain  
Since pharmacological resistance can be due to impaired interaction between the drug 
and the RTK, we performed an in silico analysis of the MET tyrosine kinase domain 
Structures were mutagenized with the PyMol Software starting from the crystal 
structure of the MET TK domain available in the NCBI structure site (NCBI 
STRUCTURE_ PDB 2WKM “X-Ray Structure Of PHA-00665752 Bound To The 
Kinase Domain Of c-MET 
http://www.rcsb.org/pdb/explore/explore.do?pdbId=2WKM). From this analysis it 
was evident that the mutations D1228N (METPRC 8) and Y1230H (METPRC 5, found 
in one lung cancer sample) conferring resistance to TKIs, were located very close to 
the ATP-binding site (Fig 3.13 A, B), while M1250T (METPRC 9), which did not 
induce resistance, was placed away from this site (Fig 3.13 C). For this reason, it is 
likely that -for steric hindrance- the ATP-competitive inhibitors (PHA-665752 and 
JNJ- 38877605) are unable to interact with their binding sites in the context of these 
mutated receptors.  
Analyzing also all the other PRC mutations (Fig 3.13 E), we observed that all the 
mutations conferring resistance were located in the proximity of the PHA-665752 
binding site, while mutated aminoacidic residues of the responsive mutants were far 
from this region. Concerning the METPRC mutant 3, that was only partially inhibited 
in presence of PHA-665752, its localization is outside the ATP binding site (see Fig 
3.13 D), suggesting the existence of a different mechanism of drug resistance.  
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Fig 3.13 
In silico analysis of MET TK domain in presence of the ATP-competitive inhibitor PHA-665752. 
In all the pictures the secondary structure of MET TK domain is green. In A, B, C, D the mutated 
aminoacidic residue is indicated by the yellow arrow and the PHA-665752 molecule is magenta. In A 
and B, red balls indicate the steric hindrance. Panel E shows the TK domain with all the PRC mutants: 
the red ones are the resistant, while the blue ones are those responsive to small molecules PHA-665752 
(the yellow structure, represented by bubbles); the partially resistant PRC 3 is orange. 
 
ALL METPRC 
MUTANTS 
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Bypassing resistance: use of an anti-MET specific monoclonal antibody 
As previously mentioned, while the presence of mutations in the intracellular TK 
domain can impair the ability to respond to small kinase inhibitors, it is likely that the 
mutated receptors are still able to respond to the inhibitory activity of monoclonal 
antibodies directed against the extracellular portion.  
One of such mAbs, named DN30, was previously produced and studied in the 
laboratory (Pietronave S, et al., 2010).  This monoclonal antibody is directed against 
the extracellular portion of the receptor and behaves as a partial agonist (Prat, M. et 
al., 1998). In fact, it induces MET activation, although at low levels, followed by  
promotion of MET down-regulation through a molecular mechanism which involves 
cleavage of the extracellular portion (also called “shedding”) of the receptor and 
proteasomal degradation of the intracellular portion (Petrelli, A. et al., 2006), (fig 3.14 
A). To eliminate the partial agonistic activity of this mAb, some colleagues at the 
IRCC have ingegnerized the antibody in order to produce a monovalent form (DN30 
FAb), which maintains only the antagonistic activity (Pacchiana G., et al., 2010). 
To evaluate the inhibitory activity of the DN30 FAb, we grew the transfected COS7 
cells for 72 hours in the presence of this molecule. We then examined the supernatant 
of the cells to look for the presence of the released MET extracellular portion. As we 
observed that FAb DN30 treatment caused “shedding” of extracellular domain in all 
METPRC mutants (fig 3.14 B) we could conclude that the DN30 FAb was indeed 
active on all the mutants. When we analyzed the activation status of the different 
mutants, we found indeed that FAb DN30 treatment resulted in their inhibition, 
independently from their sensitivity to TKIs. An example is shown in figure 3.15 
where all the TKI-resistant mutants were inhibited (and thus lost their tyrosine 
phosphorylation) and the total amount of MET decreased upon DN30 FAb treatment. 
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Fig 3.14 
Mechanism of action of the monoclonal antibody DN30 (A). This monoclonal antibody (DN-30) is 
directed against the extracellular portion of MET  and binds to MET at subnanomolar affinity, inducing 
proteolytic cleavage of the extracellular portion close to the cell membrane and release of a soluble 
receptor in the extracellular space (Petrelli, A. et al., 2006). Following ectodomain shedding, operated 
by a metalloprotease of the ADAM family, the remaining transmembrane fragment becomes substrate 
of a second protease (γ-secretase) that detaches the kinase-containing portion from the membrane and 
rapidly addresses it toward the proteasome degradation pathway (Foveau B, et al. 2009). Therefore, the 
net result of DN-30 binding to MET is (a) the generation of a soluble “decoy” MET that neutralizes 
HGF and forms heterodimers with bona fide MET (Michieli, P. et al., 2004)  and (b) the proteolytic 
degradation of the MET kinase domain. This translates into neutralization of HGF/MET-mediated 
biological activities. In picture 3.10 B is reported the ectodomain shedding of all PRC mutants and 
MET wt after Fab DN30 treatment. Upon 72h of Fab DN30 treatment (24g/ml), cells were starved for 
16hrs, then the medium collected and loaded for the western blot analysis.  As shown, FAb DN30 
treatment caused the ectodomain shedding in all mutants, including the TKI-resistant group. In these 
experiments, GTL16 cell line was used as positive control. 
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Fig 3.15  
WB analysis on COS-7 cells expressing MET WT and the METPRC mutants. 
Red rectangles highlight that FAb DN30 (28 g/ml) treatment significantly decreased the 
phosphorylation all the resistant mutants (reference numbers 3, 4, 5, 7, 8) . Also the total amount of 
MET, as a direct consequence of ectodomain shedding, was significantly decreased in cells treated with 
the antibody respect the counterpart not treated (NT) or inhibited by PHA-665752. GTL16 cells were 
used as positive control of the experiment. 
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Selective inhibition of protein tyrosine kinases is gaining importance as an effective 
therapeutic approach for the treatment of a wide range of human cancers.  
The fact that the inhibition of a single oncogene can cause the death of cancer cells 
(referred as oncogene addiction) supported the idea of using highly specific inhibitors 
directed against the oncogenic proteins. The paradigm of the clinical success of 
targeted therapies based on oncogenic addiction is represented by the use of Imatinib 
(a small kinase inhibitor directed against the cytoplasmic tyrosine kinase ABL) for the 
treatment of CML (Chronic Myeloid Leukemia) in patients bearing BCR-ABL 
translocation. The oncogenic addiction has been proven also in different biological 
contests and on different targets: Trastuzmab in HER2 over-expressing breast cancers, 
Cetuximab (anti-HER1) in CRC (Colorectal Cancer) and HNSCC (Head and Neck 
Squamous Cell Carcinoma) and Gefitinib and Erlotinib (HER1 inhibitors) in NSCLC 
(Non-Small Cell Lung Cancer) (Petrelli, A. & Giordano, S., 2008). 
However, as extensively documented,  initially successful therapy is often hampered 
by acquired resistance to the drug and subsequent relapse and this could be caused by 
different mechanisms. Nowadays, given that many patients are starting to benefit from 
the discovery of monoclonal antibodies and of small molecules targeting tyrosine 
kinases, the investigators are now trying to understand and unveil the mechanisms 
through which   neoplastic cells lose their ability to respond to these drugs (also 
named secondary resistance or acquired resistance). Luckily, it appears that the 
majority of the resistance models developed in vitro are predictive of what is observed 
in vivo and can thus help researchers in identifying and studying this crucial clinical 
problem.  
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Many different mechanisms have been demonstrated to sustain resistance to targeted 
therapies. The most common mechanism of resistance, in terms of genetic alterations 
of the target, is the presence or appearance of point mutations impairing or preventing 
the interaction between the target and the drug. The most frequent types of mutations 
are those decreasing the affinity of the drug for the target kinase domain, while 
maintaining the catalytic activity. Mutations that alter the aminoacids surrounding the 
binding site of the drug decrease the availability of the target region towards the 
inhibitor, without interfering with the ATP binding (Zhang et al., 2009). Other 
reported mutations increase the affinity of the kinase for the ATP, decreasing the 
effectiveness of the ATP-competitive inhibitors (Tanaka R, Kimura S., 2008). 
Some reports support the idea that the appearance of mutations in tumors after 
treatment with a specific TKI is the result of a process of selection of a pre-existing 
cell population. Such theory supports the idea that a small population of the tumor 
bulk a priori contains the mutation, which confers a primary resistance to these cells, 
therefore giving them a selective advantage in the presence of the inhibitor. The bulk 
tumor mass is thus killed by the drug, allowing a short period of response, lasting until 
the cells resistant to the TKI become the majority. This theory is supported by the fact 
that some of these “resistance-related mutations” can be found in a small percentage 
of tumor cells in patients that have not undergone targeted therapy (Bachleitner-
Hofmann T., et al., 2008; Kreuzer KA, et al., 2003; Roche-Lestienne C, et al., 2002).  
On the other hand, other investigators believe that the high dependence of a cell on a 
specific oncogenic survival pathway forces genomic instability, allowing the 
induction of mutations that confer resistance to the inhibitor. This genomic instability 
can induce mutations either in the drug target or in other signal transducers that 
activate alternative pathways able to sustain cell viability (Ricci C, et al., 2002). 
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About the MET gene, as previously mentioned, activating mutations have been 
described in sporadic tumors such as childhood hepatocellular carcinomas, sporadic 
papillary renal carcinomas, gastric carcinomas, lung carcinomas and head and neck 
squamous cell carcinomas. The main proof of the direct involvement of MET in 
tumorigenesis was given by the identification of germ-line activating mutations in 
patients with hereditary renal papillary carcinoma (HPRC).  
Nowadays pivotal studies in NSCLC (Non-Small Cell Lung Cancer) are ongoing 
using specific chemical and biological anti-MET inhibitors; three of them (MET 
MAb, Crizotinib, ArQule-197) are in phase III clinical trials. They act with different 
mechanisms and are directed against different portions of the MET receptor: small 
TKIs (crizotinib and ArQule-197) interact with the intracellular portion, while mAbs 
bind to the extracellular domain. It is thus very likely that mutations present in 
different parts of the receptor can differentially impact on the ability to respond to 
either of the drugs.  
Recently, MET mutations have been identified within the sema domain, 
juxtamembrane domain, and intrcellular regions in small cell and non-small cell lung 
cancers, lung adenocarcinomas, gastric cancer, renal carcinomas, and mesotheliomas  
(Ma PC, et al., 2003; Kong-Beltran M, et al. 2006;  Ma PC, et al., 2008; 
Jagadeeswaran R, et al., 2006;  Lee JH, et al., 2000). Thus, mutational activation of 
MET is not restricted to renal cancer and may be a more common mechanism by 
which MET is aberrantly activated during tumorigenesis. A few  studies have shown 
that some of these mutations induce resistance to MET kinase inhibitors (Timofeevski 
SL,  et al., 2009;  Berthou S, et al., 2004; Bellon SF, et al., 2008). Therefore, 
additional studies are required to understand the effect of MET mutations in tumor 
progression and resistance to therapy.  
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From this scenario it is clear the need of choosing the most suitable therapeutic 
approaches in order to avoid the phenomenon of pharmacologic resistance. This 
requires tailoring of the therapy using drugs able to act also in the presence of  
mutations, which could determine pharmacologic resistance to the treatment. On these 
bases, my PhD work was aimed at evaluating the activity of  some available  anti-
MET therapies targeting the MET receptor mutated in the kinase domain.  
First of all, our results demonstrated that it is possible to categorize the METPRC 
mutants in two different groups: the “responsive” group whose phosphorylation was 
inhibited in presence of PHA-665752, and the “resistant” group in which  receptor 
phosphorylation and activation are not affected by the  inhibitor.  
Second, the lack of receptor inhibition was not a dose-dependent effect, but a real 
inability to respond to the drug treatment. In fact, using PHA-665752 at two different 
concentrations: [250] nM and [500] nM (ten times higher than the IC50), tyrosine 
phosphorylation of some METPRC mutants  was not inhibited even at these high doses. 
One mutant (METPCR mutant 3) was only partially inhibited, suggesting the existence 
of a different mechanism of drug resistance.  
We then demonstrated that the phenomenon of resistance is not restricted to PHA-
665752, but is shared also by other ATP-competitive MET inhibitors, such as the JNJ-
38877605. 
To evaluate the biological meaning of these observation, we engineered NIH 3T3 
cells (that express very low levels of endogenous MET) to express METPRC mutated 
forms. We found that while -induced biological activities (such as migration, invasion 
and growth) were impaired by TKIs in cells expressing wt MET or METPRC 
“responsive mutants”, they were not affected in cells MET expressing the “resistant 
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mutants”. These results show that loss of biochemical inhibition was paralleled by 
loss of MET-dependent biological activities. 
 We then asked  how these mutations can impair or prevent the response to TKIs. Our 
results, obtained by in silico analysis, demonstrated that all the mutations belonging to 
the “resistant” group are located very close to ATP binding site. It is likely that, for 
the steric hindrance due to the conformational change in the kinase domain (as a result 
of the aminoacidic change), the ATP-competitive inhibitors -such as PHA-665752 and 
JNJ-38877605- are unable to interact with their binding sites. One other possible 
mechanism of resistance in a mutated receptor can be due to the fact that the mutation 
alters the domain conformation and leads to a decrease in the affinity for the drug: this 
is likely to happen in the case of  the mutant number 3, (which showed dose-
dependent resistance) in which the mutation  is localized outside the drug binding site. 
In the era of targeted therapies, the phenomenon of resistance related to target’s 
genetic mutations is extremely important in order to better treat tumors containing 
mutations.  In the few lung tumors we examined, we found indeed a case presenting a 
METPRC mutation. Most importantly,  the identified  mutation (Y1230H) belongs to 
the “resistant” group. It is thus likely that treatment with a TKI of a patient bearing 
such a mutant receptor will not end with a favorable outcome.  
At this point, we wondered if we could figure a therapeutic approach which  could 
represent an alternative treatment for patients with tumors carrying MET mutants 
resistant to TKIs. Such an approach could be the use of a monoclonal antibody 
directed again the extracellular portion of the receptor, which is in the wild type 
conformation also in the METPRC mutants.  
We thus treated cells expressing the METPRC mutants with the monomeric form of an 
anti-MET monoclonal antibody (FAb DN30). Indeed, we found that the antibody was 
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able to inhibit all TKI mutants, independently from their sensitivity to small TKIs.  
These results indicate that despite some mutated forms are unable to respond to small 
molecule TKIs, they still remain responsive to treatment with antibodies directed 
against the MET extracellular portion, likely because the extracellular domain is in the 
wild type conformation. In clinical terms, these data show that we can “bypass” 
resistance to TKIs by use of mAbs directed against the MET extracellular portion. In 
conclusion, our results  indicate that in tumors harboring MET tyrosine kinase 
mutations that prevent or impair the interaction between the ATP-competitive TKIs 
and the receptor, the use of small molecule TKI could be inappropriate.  
We propose that the use of specific anti-MET monoclonal antibodies (such as FAb 
DN30) can represent, a therapeutic alternative to treat TKIs-resistant tumors harboring 
mutations in the MET tyrosine kinase domain, Our data could thus help in better 
tailoring the anti-MET targeted therapies, thus contributing to increasing their 
effectiveness.  
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MATERIALS AND METHODS 
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Plasmid constructs and mutagenesis 
pCEV29.1 expression vector was available in the lab wt MET cDNA was cloned in 
the vector as described (Giordano et al., 2000)  and  PRC mutations were introduced 
in  by polymerase chain reaction (Bardelli, A. et al., 1998). Human MET residues are 
numbered according to Gene Bank# X54559 (Ponzetto, C. et al., 1991).  
The human MET cDNA cloned in the plasmidic construct pRLL2 was available in the 
lab, then mutagenized by using the QuikChange II XL Site-Directed Mutagenesis Kit 
(Agilent Thechnologies). The QuikChange II site-directed mutagenesis kit is used to 
make point mutations, replace amino acids, and delete or insert single or multiple 
adjacent amino acids. This mutagenesis’ method was performed using PfuUltra high-
fidelity (HF) DNA polymerase for mutagenic primer-directed replication of both 
plasmid strands with the highest fidelity. The basic procedure utilizes a supercoiled 
double-stranded DNA (dsDNA) vector with an insert of interest and two synthetic 
oligonucleotide primers, both containing the desired mutation.  The oligonucleotide 
primers, each complementary to opposite strands of the vector, are extended during 
temperature cycling by PfuUltra HF DNA polymerase, without primer displacement. 
Extension of the oligonucleotide primers generates a mutated plasmid containing 
staggered nicks. Following temperature cycling, the product is treated with Dpn I. The 
Dpn I endonuclease (target sequence: 5´-Gm6ATC-3´) is specific for methylated and 
hemimethylated DNA and is used to digest the parental DNA template and to select 
for mutation-containing synthesized DNA. The nicked vector DNA containing the 
desired mutations is then transformed into competent cells. 
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Transfection, infection 
COS-7 cells were transfected by the DEAE-dextran method. Briefly, plasmid DNA (2 
g/ml) was resuspended in DMEM containing DEAE-dextran and added to a 100-mm 
dish of subconfluent COS 7 cells. Dimethyl sulfoxide shock was performed after 4 h 
of incubation at 37°C.   
Lentiviruses were produced by transient transfection of 293T cells whit the calcium-
phosphate procedure containing the DNA to be transfected, as described elsewhere 
(Vigna and Naldini, 2000). Cell infection was performed over-night and in the 
presence of polybrene (hexadimethrine bromide). Polybrene is a relatively non-toxic 
polymer, that was shown to enhance the adsorption of virus complex onto cells in 
culture (Coelen et al., 1983). 
 
Cell culture 
293T, GTL16, A549, COS-7 and NIH 3T3 cell lines from ATCC were cultivated in 
DMEM (293T, NIH 3T3) or RPMI (GTL16 and A549) supplemented with 1% Q, 
0.1% penicillin (5000U/ml, Faber), 0.1% streptomycin (5mg/ml, Squibb) and with 
10% FBS or Calf Serum deactivated by heating (NIH 3T3), at 37°C in 5% CO2. 
 
Protein extraction and Western blot 
For Western blot analysis, cells were lysed in boiling LB buffer [2% SDS, 0.5 mol/L 
Tris-HCl (pH 6.8)]. Protein concentration of whole-cell lysates was evaluated with the 
BCA Protein Assay kit (Pierce) and equal amounts of total proteins were analyzed by 
SDS-PAGE and Western blotting. Western blots were performed according to 
standard methods. The antibodies used were as follows: anti-MET antibody DL21  
(Prat, M. et al. 1998) and anti-MET Zymed (Invitrogen), anti-phospho MET 
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Tyr1349/1356 (Cell Signaling Technology). Final detection was done with enhanced 
chemiluminescence (ECL) system (Amersham). 
 
Biological assays 
For invasion assays, cells were seeded in Transwell chamber, on the upper side of a 
porous polycarbonate membrane. The medium in both chambers was supplemented 
with low percentage serum; the lower chamber was supplemented with HGF (20 
ng/ml) alone or in presence of JNJ-38877605 (Johnson and Johnson) [500] nM. After 
16 h, cells attached on the upper side of the membrane were mechanically removed. 
Cells that migrated to the lower side were fixed with gluataraldehyde and stained with 
crystal violet. Stained cells were photographed.  
For analysis of colony formation in soft agar, cells were diluted to a concentration of 
7x10
3 
cells/ml in DMEM containing 10% FBS and 0.5% Seaplaque agar, with HGF 
(20 ng/ml), in presence or absence of JNJ-38877605. Cells were seeded in 12-well 
plates (1 ml per well) containing a 1% agar underlay and supplemented twice a week 
with DMEM containing 10% FBS and, where indicated, HGF and JNJ-38877605. 
Colonies were stained with tetrazolium salts three weeks after seeding and the 
viability was evaluated using the alamarBlue® cell viability reagent (Invitrogen). This 
reagent is used to assess cell viability by  adding the 10X, ready-to-use solution to 
cells in culture media, followed by a 1–4 hours incubation at 37ºC (to allow cells to 
convert resazurin to resorufin). The resulting fluorescence was read on a 96-well plate 
reader.  
For the wound healing assay, NIH 3T3 cells were plated to create a confluent 
monolayer. After scraping the cell monolayer with a p200 pipet tip, cells were washed 
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and the media replaced with DMEM 10% serum alone, or HGF (20 ng/ml), or HGF 
(20 ng/ml) in presence of JNJ-38877605. Cells dishes were incubated for 24-48 hrs. 
The migration assay was stopped when the wound was repaired, the cells were fixed 
in glutheraldeide then stained with crystal violet and photographed. 
 
Tumor samples collection 
Tumor samples were obtained in accordance with consent procedures approved by the 
Ethic Committee of Hospital San Giovanni Battista (Turin) and the University Of 
Cagliari.   The follow-up reports, was adapted to the new guidelines in the 7th Edition 
of TNM in Lung Cancer of the International Association for the Study of Lung 
Cancer (IASLC). 
 
RNA extraction, RT-PCR , PCR and sequencing  
Total RNA was extracted from lung tumors using Trizol reagent (Invitrogen) 
according to the manufacturer's instructions. RNA (500 ng)  was retrotranscribed into 
cDNA using the High Capacity cDNA Reverse Transcription Kit containing the 
Multiscribe Reverse Transcriptase (Applied Biosystem). 
The cDNA coding for the MET intracellular domain was amplified by polymerase 
chain reaction (PCR). To increase the PCR specificity, sensitivity and yield, without 
the need for lengthy optimizations and/or the redesigning of primers specificity, we 
performed the Touch Down PCR (TD-PCR) using the TaqGold polymerase 
(Applied). TD-PCR employs an initial annealing temperature above the projected 
melting temperature (Tm) of the primers being used, then progressively transitions to 
a lower, more permissive annealing temperature over the course of successive cycles. 
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Any difference in Tm between correct and incorrect annealing will produce an 
exponential advantage of twofold per cycle ( Korbie &  Mattick, 2008).   
Then amplified segments were purified using the chemical method named Solid Phase 
Reversible Immobilization (SPRI) based on speed beads (Agencourt Ampure Xp Kit), 
and finally sequenced by the Sanger’s method (Sanger F, Coulson AR , 1975).  
The mutational analysis, was performed by using the Mutation Surveyor® DNA variant 
analysis of Sanger Sequencing software,  manufactured by SoftGenetics (Pennsylvania, 
USA). 
 
In silico analysis 
The in silico analysis of the MET tyrosine kinase domain, was performed using the 
software PyMOL. PyMOL is one of a few open source visualization tools available 
for use in structural biology (http://pymol.org/). The Py portion of the software's name 
refers to the fact that it extends, and is extensible by the Python programming 
language. Using PyMOL, the MET TK structure was mutagenized from: “X-Ray 
Structure Of PHA-00665752 Bound To The Kinase Domain Of c-Met”, Source: 
NCBI Structure_ Protein Date Bank (PDB) 2WKM (see 
http://www.rcsb.org/pdb/explore.do?structureId=2wkm). 
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